Table 3.
Associations between AIB1 genotypes and breast cancer risk by histologic subtype and receptor status
| No of AIB1 alleles | ||||
| with ≤26 repeats | ||||
| Controls/cases | 0 | 1 or 2 | OR* | 95% Cl |
| Controls | 483 | 141 | ||
| Cases† | ||||
| Invasive | 295 | 93 | 1.13 | 0.83-1.54 |
| Ductal | 252 | 79 | 1.10 | 0.81-1.53 |
| Lobular | 33 | 9 | 1.05 | 0.48-2.30 |
| Involved nodes | ||||
| ≥ 1 | 83 | 24 | 1.07 | 0.64-1.78 |
| ≥ 4 | 30 | 6 | 0.72 | 0.29-1.81 |
| Receptor status | ||||
| ER+ | 189 | 61 | 1.16 | 0.81-1.65 |
| ER- | 46 | 12 | 0.94 | 0.47-1.85 |
| PR+ | 142 | 45 | 1.14 | 0.77-1.69 |
| PR- | 86 | 24 | 1.03 | 0.63-1.71 |
| Tumor size | ||||
| ≤ 2 cm | 207 | 64 | 1.13 | 0.80-1.60 |
| > 2 cm | 74 | 25 | 1.21 | 0.73-2.00 |
| Degree of differentiation | ||||
| High or | 98 | 37 | 1.36 | 0.89-2.10 |
| moderate | ||||
| Poor | 55 | 23 | 1.54 | 0.90-2.64 |
*Unconditional logistic regression adjusted for matching variables: age, menopausal status, postmenopausal hormone use, date of blood sampling, time of blood sampling and fasting status. †Numbers do not add up to total for invasive cancer because of missing data.